Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, has reported the grant of 3,500 restricted stock units of its common stock to a newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of October 1, 2024.
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date. The remainder vests in 12 approximately equal quarterly installments over the following three years, subject to continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the new employee entering into employment with Atara.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), leader nell'immunoterapia con cellule T, ha annunciato il conferimento di 3.500 unità di azioni ristrette delle sue azioni ordinarie a un nuovo dipendente assunto. Questo premio è stato approvato dal Comitato per la Remunerazione del Consiglio di Amministrazione di Atara ed è stato concesso ai sensi del Piano di Induzione 2018 di Atara Biotherapeutics, Inc., con data di concessione 1 ottobre 2024.
Le unità di azioni ristrette maturano nel corso di quattro anni, con il 25% che matura alla prima data di maturazione trimestrale successiva al primo anniversario della data di inizio della maturazione. Il resto matura in 12 rate trimestrali di valore approssimativamente equivalente nei successivi tre anni, soggetto a impiego continuativo. Questa concessione è stata effettuata in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come incentivo materiale per il nuovo dipendente che entra in servizio con Atara.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), líder en inmunoterapia con células T, ha informado sobre la concesión de 3,500 unidades de acciones restringidas de sus acciones ordinarias a un nuevo empleado contratado. Este premio fue aprobado por el Comité de Compensación de la Junta Directiva de Atara y se otorgó bajo el Plan de Inducción 2018 de Atara Biotherapeutics, Inc., con fecha de concesión del 1 de octubre de 2024.
Las unidades de acciones restringidas se consolidan durante cuatro años, con el 25% consolidándose en la primera fecha de consolidación trimestral después del primer aniversario de la fecha de inicio de la consolidación. El resto se consolida en 12 pagos trimestrales aproximadamente iguales durante los siguientes tres años, sujeto a empleo continuo. Esta concesión se realizó de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4) como un incentivo material para el nuevo empleado al ingresar en su puesto con Atara.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA)는 T세포 면역 요법의 선두주자로, 새로 고용된 직원에게 3,500개의 제한 주식 유닛을 부여했다고 발표했습니다. 이 상은 Atara의 이사회 보상위원회에 의해 승인되었으며, Atara Biotherapeutics, Inc.의 2018 유인 계획에 따라 부여되어, 부여 날짜는 2024년 10월 1일입니다.
제한 주식 유닛은 4년 동안 분배되며, 첫 번째 분배 시작 날짜의 첫 번째 기념일 이후 첫 분기 분배일에 25%가 분배됩니다. 나머지는 다음 3년 동안 12회의 약 동일한 분기별 할부로 분배되며, 지속적인 고용을 조건으로 합니다. 이 부여는 Atara에 신규 고용된 직원이 근무하는 중요한 유인으로서 NASDAQ 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), un leader de l'immunothérapie par cellules T, a annoncé l'octroi de 3 500 unités d'actions restreintes de ses actions ordinaires à un nouvel employé embauché. Cette récompense a été approuvée par le comité de rémunération du conseil d'administration d'Atara et a été accordée dans le cadre du Plan d'Induction 2018 d'Atara Biotherapeutics, Inc., avec une date d'octroi du 1er octobre 2024.
Les unités d'actions restreintes deviennent acquises sur une période de quatre ans, avec 25 % devenant acquises à la première date de maturité trimestrielle après le premier anniversaire de la date de début de la maturité. Le reste devient acquis en 12 versements trimestriels d'une valeur à peu près égale sur les trois années suivantes, sous réserve d'un emploi continu. Cet octroi a été effectué conformément à la règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation matérielle pour le nouvel employé entrant en service chez Atara.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), führend in der T-Zell-Immuntherapie, hat die Gewährung von 3.500 beschränkten Aktieneinheiten ihres Stammkapitals an einen neu eingestellten Mitarbeiter bekannt gegeben. Diese Auszeichnung wurde vom Vergütungsausschuss des Vorstands von Atara genehmigt und im Rahmen des Atara Biotherapeutics, Inc. 2018 Inducement Plans mit einem Gewährungsdatum vom 1. Oktober 2024 gewährt.
Die beschränkten Aktieneinheiten werden über vier Jahre fällig, wobei 25 Prozent am ersten vierteljährlichen Fälligkeitsdatum nach dem ersten Jahrestag des Fälligkeitsbeginns fällig werden. Der Rest wird in 12 annähernd gleichmäßigen vierteljährlichen Raten über die folgenden drei Jahre fällig, insbesondere bei fortlaufender Beschäftigung. Diese Gewährung erfolgte gemäß der Nasdaq-Listing-Regel 5635(c)(4) als wesentlicher Anreiz für den neuen Mitarbeiter, der bei Atara anfängt.
- Atara Biotherapeutics is attracting new talent with stock-based compensation
- None.
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004846897/en/
Investor and Media Relations:
Jason Awe, Ph.D.
Head of Corporate Communications & Investor Relations
(805) 217-2287
jawe@atarabio.com
Source: Atara Biotherapeutics, Inc.
FAQ
How many restricted stock units did Atara Biotherapeutics (ATRA) grant to the new employee?
What is the vesting schedule for the restricted stock units granted by Atara Biotherapeutics (ATRA)?
Under which plan were the restricted stock units granted by Atara Biotherapeutics (ATRA)?
What is the grant date of the restricted stock units issued by Atara Biotherapeutics (ATRA)?
